-
1.发明申请公开(公告)号：US20050267201A1
公开(公告)日：2005-12-01
申请号：US11165896
申请日：2005-06-24
申请人： Jose Gutierrez-Rocca , Janice Cacace , Sami Selim , Robert Testman , J. Rutledge
发明人： Jose Gutierrez-Rocca , Janice Cacace , Sami Selim , Robert Testman , J. Rutledge
IPC分类号： A61K9/10 , A61F2/02 , A61K9/107 , A61K9/20 , A61K9/48 , A61K9/64 , A61K31/335 , A61K31/337 , A61K38/13 , A61K45/06 , A61K47/10 , A61K47/14 , A61K47/22 , A61K47/40 , A61K47/44 , A61P1/16 , A61P1/18 , A61P13/08 , A61P13/12 , A61P33/06 , A61P35/00
CPC分类号： A61K9/4858 , A61K9/1075 , A61K9/4866 , A61K31/335 , A61K31/337 , A61K38/13 , A61K45/06 , A61K47/10 , A61K47/14 , A61K47/22 , A61K47/40 , Y02A50/411 , A61K2300/00
摘要： Pharmaceutical compositions for oral administration to mammalian subjects comprise a taxane or taxane derivative (e.g., paclitaxel or docetaxel) as active ingredient and a vehicle comprising at least 30% by weight of a carrier for the taxane, said carrier having an HLB value of at least about 10. The compositions may also comprise 0-70% of a viscosity-reducing co-solubilizer. The compositions may be incorporated into conventional oral pharmaceutical dosage forms, or can be in the form of a two-part medicament wherein the first part includes the taxane in a solubilizing vehicle and the second part comprises a carrier for the taxane to promote oral absorption. Methods of treatment of taxane-responsive disease conditions employing the novel compositions are also disclosed, whereby the compositions can be administered alone or in association with an oral bioavailability enhancing agent.
-
公开(公告)号：US20100209511A1
公开(公告)日：2010-08-19
申请号：US12765092
申请日：2010-04-22
申请人： Jose Gutierrez-Rocca , Saul Rios
发明人： Jose Gutierrez-Rocca , Saul Rios
IPC分类号： A61K9/10 , A61K31/495 , A61K31/135 , A61K31/4406 , A61K31/522 , A61K31/554 , A61K31/155 , A61K31/4164 , A61P43/00
CPC分类号： A61K9/2027 , A61K9/2054
摘要： A sustained release pharmaceutical formulation is disclosed. The formulation comprises a water soluble medicament and a polymer mixture comprising a first component of about 80 weight percent polyvinylacetate combined with about 20 weight percent polyvinyl pyrrolidone; of the total weight of the first component, combined with a second component of a cellulose ether polymer.
摘要翻译： 公开了缓释药物制剂。 该制剂包含水溶性药物和聚合物混合物，其包含约80重量％聚乙酸乙烯酯与约20重量％聚乙烯吡咯烷酮结合的第一组分; 的第一组分的总重量，与纤维素醚聚合物的第二组分组合。
-
公开(公告)号：US07056957B2
公开(公告)日：2006-06-06
申请号：US10827841
申请日：2004-04-20
IPC分类号： C08F8/00 , C08F8/44 , C08F251/00
CPC分类号： C08F251/00 , A61L27/20 , A61L27/52 , A61L27/56 , A61L31/042 , A61L31/145 , A61L31/146 , C08F2/44 , C08F8/44 , C08F251/02 , C08J3/075 , C08J9/08 , C08J9/28 , C08J9/40 , C08J2201/024 , C08J2201/0546 , C08J2203/02 , C08J2205/02 , C08J2205/022 , C08J2300/14 , C08J2301/28 , C08L2205/04
摘要： The present invention features a method for the formation of superporous hydrogels using an ion-equilibration technique. Anionic polysaccharides are included in the hydrogel reaction mixture and cations are introduced either during or after hydrogel formation. Properties of the resulting hydrogel can be subsequently adjusted by treating the cation-complexed gel with a different cation or cation mixture under equilibrating conditions. It has been found that by properly adjusting the cations and the sequence in which they are used in the equilibration process, superporous hydrogels can be formed that are highly absorbent while maintaining favorable structural properties, including strength, ruggedness, and resiliency. It has also been found that applying appropriate dehydration conditions to them after their formation can further stabilize the superporous hydrogels formed by the method of the invention.
摘要翻译： 本发明的特征在于使用离子平衡技术形成多孔水凝胶的方法。 在水凝胶反应混合物中包含阴离子多糖，并且在水凝胶形成期间或之后引入阳离子。 随后通过在平衡条件下用不同的阳离子或阳离子混合物处理阳离子络合的凝胶来调节所得水凝胶的性质。 已经发现，通过在平衡过程中适当地调节阳离子及其使用顺序，可以形成高吸水性的多孔水凝胶，同时保持有利的结构特性，包括强度，耐久性和弹性。 还已经发现，在其形成后对它们施加适当的脱水条件可以进一步稳定通过本发明的方法形成的多孔水凝胶。
-
公开(公告)号：US20070264332A1
公开(公告)日：2007-11-15
申请号：US11782886
申请日：2007-07-25
申请人： Jose Gutierrez-Rocca , Saul Rios
发明人： Jose Gutierrez-Rocca , Saul Rios
IPC分类号： A61K9/22 , A61K31/135 , A61K31/166 , A61K31/40 , A61K31/4164 , A61K31/437 , A61K31/455 , A61K31/495 , A61K31/496 , A61K31/522 , A61K31/554
CPC分类号： A61K9/2027 , A61K9/2054
摘要： A sustained release pharmaceutical formulation is disclosed. The formulation comprises a water soluble medicament and a polymer mixture comprising a first component of about 80 weight percent polyvinylacetate combined with about 20 weight percent polyvinyl pyrrolidone; of the total weight of the first component, combined with a second component of a cellulose ether polymer.
摘要翻译： 公开了缓释药物制剂。 该制剂包含水溶性药物和聚合物混合物，其包含约80重量％聚乙酸乙烯酯与约20重量％聚乙烯吡咯烷酮结合的第一组分; 的第一组分的总重量，与纤维素醚聚合物的第二组分组合。
-
公开(公告)号：US06596308B2
公开(公告)日：2003-07-22
申请号：US10212484
申请日：2002-08-05
IPC分类号： A61K948
CPC分类号： A61K9/4866 , A61K9/4858
摘要： A sustained/prolonged release pharmaceutical dosage form is disclosed. The form comprises a hard shell capsule and a formulation comprising (a) a water insoluble medicant, (b) a high melting fatty ester, (c) a low viscosity oil, (d) a cellulosic polymer, and (e) a non-ionic surfactant.
摘要翻译： 公开了持续/延长释放的药物剂型。 该形式包括硬壳胶囊和制剂，其包含（a）水不溶性药物，（b）高熔点脂肪酸酯，（c）低粘度油，（d）纤维素聚合物，和（e） 离子表面活性剂。
-
公开(公告)号：US06524615B2
公开(公告)日：2003-02-25
申请号：US09790239
申请日：2001-02-21
IPC分类号： A61K948
CPC分类号： A61K9/4866 , A61K9/4858
摘要： A sustained/prolonged release pharmaceutical dosage form is disclosed. The form comprises a hard shell capsule and a formulation comprising (a) a water insoluble medicament, (b) a high melting fatty ester, (c) a low viscosity oil, (d) a cellulosic polymer, and (e) a non-ionic surfactant.
-
公开(公告)号：US06491950B1
公开(公告)日：2002-12-10
申请号：US09649776
申请日：2000-08-29
IPC分类号： A61K914
CPC分类号： A61K9/4858
摘要： A controlled release pharmaceutical formulation is disclosed. The formulation comprises a construct having a matrix of a material selected from the group comprising (a) a high melting point fatty acid ester, (b) an oil, (c) a polymeric cellulose derivative and (d) a mixture of any of the foregoing. Associated with the matrix is a selected medicament. Preferably, the matrix comprises at least two of the aforementioned materials or components.
摘要翻译： 公开了一种控释药物制剂。 制剂包含具有选自以下的材料的基质的构建体，所述基质包括（a）高熔点脂肪酸酯，（b）油，（c）聚合纤维素衍生物和（d） 前面的。 与基质相关的是选定的药物。 优选地，基质包括至少两种上述材料或组分。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.03 秒)
